Latest

Tourette Syndrome Pipeline 2026: Investigational Therapies, Clinical Trial Advances, and Key Regulatory Developments by DelveInsight

25 March 2026
According to DelveInsight’s latest evaluation, the global Tourette syndrome treatment pipeline features more than 6 prominent companies actively advancing over 6 investigational therapies. The comprehensive assessment covers ongoing clinical trials, therapeutic candidates, mechanisms of action, administration routes, and notable developmental milestones. The

Polycystic Ovarian Syndrome (PCOS) Pipeline 2026: Emerging Treatments, Clinical Trial Progress, and Regulatory Updates by DelveInsight

25 March 2026
According to DelveInsight’s latest evaluation, the global Polycystic Ovarian Syndrome (PCOS) development pipeline features more than 4 prominent pharmaceutical companies actively engaged in advancing over 5 therapeutic candidates. The assessment encompasses a thorough analysis of ongoing clinical trials, investigational therapies, mechanisms of

Comprehensive Insights into Advancing Therapies, Epidemiology Trends, and Future Growth of Myeloproliferative Neoplasms Market Landscape

24 March 2026
The evolving landscape of rare hematologic malignancies continues to draw increasing attention from researchers, healthcare providers, and pharmaceutical companies worldwide. Among these conditions, myeloproliferative neoplasms (MPNs) represent a complex and clinically significant group of disorders that are witnessing notable advancements in diagnosis

Coronary Microvascular Dysfunction Market Size in the 7MM is expected to grow at a significant CAGR by 2034, estimates DelveInsight

20 March 2026
DelveInsight’s “Coronary Microvascular Dysfunction Market Insight, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of Coronary Microvascular Dysfunction, historical and forecasted epidemiology as well as the Coronary Microvascular Dysfunction market trends in the United States, EU4 (Germany, France, Italy,

Nonalcoholic Steatohepatitis Market Size (7MM) was ~USD 2,114 million in 2023 and is projected to increase at a significant CAGR by 2034, estimates DelveInsight

20 March 2026
DelveInsight’s “Nonalcoholic Steatohepatitis Market Insight, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of Nonalcoholic Steatohepatitis, historical and forecasted epidemiology as well as the Nonalcoholic Steatohepatitis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and
1 14 15 16 17 18 31